Zhang Yan, Xie Meilin, Xue Jie, Gu Zhenlun
Department of Pharmacology, Medical School of Soochow University, Suzhou, PR China.
Planta Med. 2007 Jul;73(8):718-24. doi: 10.1055/s-2007-981552. Epub 2007 Jul 5.
The objectives of this study were to determine the therapeutic effect of osthole, an active constituent isolated from Cnidium monnieri (L.) Cusson (Apiaceae), in hyperlipidemic fatty liver (HFL) rats and investigate the possible mechanism of the osthole treatment. The HFL rat model was established by feeding Sprague-Dawley rats with fat milk for 6 weeks. The experimental rats were then treated with a dose of osthole of 5 - 20 mg/kg for 6 weeks. After the treatment, total cholesterol (TC) and triglycerides (TG) in serum and hepatic tissue, as well as the coefficient of hepatic weight were measured. The results showed that the TC and TG in both serum and hepatic tissue and the coefficient of hepatic weight in the osthole-treated rats were lower as compared to those in the experimental group, respectively (P < 0.05 or P < 0.01). Moreover, as compared to the control group, the osthole treatment increased the PPARalpha/gamma mRNA expression by 58.0 - 84.0 % and 20.4 - 77.4 %, respectively. The related target genes for mRNA expression were also increased by osthole-treatment, e. g., 53.4 - 93.2 % for CYP7A, 21.1 - 63.2 % for L-FABP and 34.1 - 57.3 % for FATP4, while the DGAT mRNA expression was decreased by 26.0 - 44.4 %. The therapeutic effect of osthole was further confirmed by histological evaluation of the liver showing a dramatically decreased lipid accumulation and improved ultrastructure of hepatocytes. In conclusion, osthole exerts therapeutic effects on fat milk-induced fatty liver in rats, by regulating mRNA expression of the target genes of CYP7A, DGAT, L-FABP and FATP4 via increasing the PPARalpha/gamma mRNA expression.
本研究的目的是确定蛇床子素(从伞形科植物蛇床子中分离出的一种活性成分)对高脂血症性脂肪肝(HFL)大鼠的治疗效果,并探讨蛇床子素治疗的可能机制。通过给Sprague-Dawley大鼠喂食高脂乳剂6周建立HFL大鼠模型。然后将实验大鼠用5 - 20 mg/kg剂量的蛇床子素治疗6周。治疗后,测量血清和肝组织中的总胆固醇(TC)和甘油三酯(TG)以及肝脏重量系数。结果表明,与实验组相比,蛇床子素治疗组大鼠血清和肝组织中的TC和TG以及肝脏重量系数均较低(P < 0. = 05或P < 0.01)。此外,与对照组相比,蛇床子素治疗使PPARα/γ mRNA表达分别增加了58.0 - 84.0%和20.4 - 77.4%。蛇床子素治疗还使mRNA表达的相关靶基因增加,例如,CYP7A增加53.4 - 93.2%,L-FABP增加21.1 - 63.2%,FATP4增加34.1 - 57.3%,而DGAT mRNA表达降低26.0 - 44.4%。肝脏组织学评估进一步证实了蛇床子素的治疗效果,显示脂质蓄积显著减少,肝细胞超微结构得到改善。总之,蛇床子素通过增加PPARα/γ mRNA表达来调节CYP7A、DGAT、L-FABP和FATP4靶基因的mRNA表达,从而对高脂乳剂诱导的大鼠脂肪肝发挥治疗作用。